Hematology, Transfusion and Cell Therapy最新文献

{"title":"EVALUATION OF ANTIPROLIFERATIVE OF A POTENTIAL THERAPEUTIC ASSOCIATION OF SILVER COMPLEXES WITH LIMONENE IN SQUAMOUS CELL CARCINOMA AND MELANOMA CELL LINES","authors":"Daniele Daiane Affonso, Juliana Carron, Francisco Mastrobuono Cordeiro de Almeida, Gabriele de Menezes Pereira, João Ernesto de Carvalho, Pedro Paulo Corbi, Ana Lucia Tasca Gois Ruiz, Carmen Silvia Passos Lima","doi":"10.1016/j.htct.2025.103766","DOIUrl":"10.1016/j.htct.2025.103766","url":null,"abstract":"<div><h3>Introduction/Justification</h3><div>Skin cancer, strongly associated with UV exposure, is the most common malignancy worldwide, including squamous cell carcinoma (SCC), and cutaneous melanoma (CM). Although cisplatin and 5-FU are standard treatments for SCC and CM, the development of new therapeutic alternatives is crucial. Silver complexes have shown promising anticancer potential, while the monoterpene limonene has demonstrated efficacy in enhancing skin permeation, supporting its application in topical drug delivery.</div></div><div><h3>Objectives</h3><div>Our study aimed to evaluate the in vitro antiproliferative effects of silver complexes and limonene, isolated and in association.</div></div><div><h3>Materials and Methods</h3><div>The silver complexes identified as I and II were synthesized at the Institute of Chemistry of University of Campinas. The pure substances R-(+)-limonene and S-(-)-limonene were acquired from Merck. Pharyngeal SCC (FaDU) and melanoma (A-375, SK-MEL-28) cells (4 × 10³ cells/mL) were treated with complexes I e II (0.4–400 µM) or their combination with R-(+) and S-(-) limonene (4 µM). Cisplatin and 5-FU (100 μL/well, 0.4 to 400 µg/mL, in triplicate) were used as positive controls. Before (T0) and after (T1) sample addition, cells were fixed with 50% trichloroacetic acid (TCA, 50 μL/well), and were then resuspended in Tris base for subsequent absorbance at 540 nm with a microplate reader spectrophotometer (VersaMax, Molecular Devices). The difference between T0 and T1 absorbance values represented 100% cell growth. Effective concentration representing the sample concentration required to promote 50% growth inhibition (IC50) for each cell line was calculated by sigmoidal regression using Origin 8.0 software. The Combination Reduction Index (CRI) was calculated as IC 50 of the metal complex + monoterpene / IC 50 of the metal complex alone.</div></div><div><h3>Results</h3><div>Both silver complexes exhibited potent antiproliferative activity. The antiproliferative effect of silver complex I ranged from 4 µM to 10 µM in SCC and CM cell lines, whereas the antiproliferative effect of silver complex II ranged from 1 µM to 6 µM in the same cell lines. The association of silver complex I in combination with S-(-)-limonene resulted in synergism effect in the FaDu cell line with IC50 < 2 µM, CRI = 0.4. The association of silver complex II with both enantiomers demonstrated a partial synergistic effect in the FaDu and SK-MEL-28 cells, with IC50 <1.5 µM and CRI = 0.5.</div></div><div><h3>Conclusion</h3><div>Silver complexes are promising candidates for in vivo studies as potential alternatives for the treatment of patients with SCC and CM. Additional experiments are necessary to evaluate their mechanism of action and toxicity. The study was supported by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Fundação de Apoio ao Ensino e à Pesquisa do Estado de São Paulo (FAPESP #2016/07729-4; #2023/0973","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 ","pages":"Article 103766"},"PeriodicalIF":1.8,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143829747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COMPARISON BETWEEN MANUAL AND AUTOMATIC SEGMENTATION OF THE WHOLE-BRAIN AND CEREBELLUM","authors":"Marcos Paulo Dias de Sá e Silva ,&nbsp;Maria Emília Seren TAKAHASHI ,&nbsp;Tiago Pessolo Dos Santos ,&nbsp;Carmino Antonio De Souza ,&nbsp;Celso Darío Ramos","doi":"10.1016/j.htct.2025.103770","DOIUrl":"10.1016/j.htct.2025.103770","url":null,"abstract":"<div><h3>Introduction/Justification</h3><div>18F-FDG PET/CT is widely used to quantify brain metabolic activity and plays a key role in studying various diseases. Segmentation method choice can significantly influence standardized uptake value (SUV) measurements, thereby affecting the accuracy of the analysis. The Beth Israel Plugin in ImageJ allows both manual and automatic segmentation, making it relevant for evaluating differences in brain and cerebellum analysis.</div></div><div><h3>Objectives</h3><div>This study aims to compare the mean, maximum, and peak SUVs obtained through manual and automatic (Grow Mask) segmentation of the brain and cerebellum, assessing the relative percentage differences and variations between the methods.</div></div><div><h3>Materials and Methods</h3><div>Seventy-three multiple myeloma (MM) patients who underwent 18F-FDG PET/CT were included in the study, comprising 43 men (58.9%) with a mean age of 64.2 ± 11.4 years. Brain segmentation was performed in FIJI using two methods: (1) manual segmentation (MS) consisting of a spherical volume of interest (VOI) of 6.7 mL for the cerebellum and 377 mL for the brain and (2) auto-segmentation (AS) using a Grown Mask algorithm. Manual cropping of PET images was performed before AS to exclude non-cerebellar regions. The relative percentage difference between the two methods was calculated as (1 - MS/AS). Mean, maximum and peak SUVs (SUVmean, SUVmax and SUVpeak, respectively), as well as maximum and minimum variation ranges of SUVs between MS and AS, were recorded.</div></div><div><h3>Results</h3><div>For the brain, SUVs were higher for AS compared to MS: SUVmean = 4.19 ± 0.02 (MS) vs. 5.99 ± 0.03 (AS), corresponding to 30.05% difference (range: 10.21% to 41.39%); SUVpeak = 8.07 ± 0.05 (MS) vs. 9.05 ± 0.06 (AS), 10.83% difference (range: 0% to 40.59%); and SUVmax = 10.76 ± 0.06 (MS) vs. 11.75 ± 0.07 (AS), 8.43% difference (range: 0% to 55.46%). For the cerebellum, a greater variability between MS and AS SUVs were found: SUVmean = 6.00 ± 0.03 (MS) vs. 5.47 ± 0.02 (AS), corresponding to -9.69% difference (range: 0% to 53.51%); SUVpeak = 7.06 ± 0.03 (MS) vs. 7.29 ± 0.03 (AS), 3.15% difference (range: 0% to 32.96%); SUVmax = 8.23 ± 0.04 (MS) vs. 9.20 ± 0.04 (AS), 10.54% difference (range: 0% to 42.57%).</div></div><div><h3>Conclusion</h3><div>The choice of segmentation method significantly impacts SUV values. AS yielded higher brain SUVs, while cerebellum MS showed greater variability due to manual adjustments and VOI selection. The differences between methods stem from segmentation techniques: MS used a spherical VOI, sometimes excluding the highest SUV point, whereas AS encompassed the full structure, capturing the true SUVmax. Thus, spherical VOI is less precise for whole-organ analysis but useful for quick regional calculations. Standardizing segmentation methods is crucial for reliable comparisons in clinical and research settings.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 ","pages":"Article 103770"},"PeriodicalIF":1.8,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143829761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FDG PET/CT AND PSMA PET/CT IN MUSCULOSKELETAL SOFT TISSUE SARCOMAS","authors":"Ellen Nogueira Lima ,&nbsp;Thaisa Ramos Freire ,&nbsp;Mayara Branco E. Silva ,&nbsp;Natalia Tobar Toledo Prudente Silva ,&nbsp;Thiago Alves ,&nbsp;Allan Santos ,&nbsp;Mariana Lima ,&nbsp;José Carvalheira ,&nbsp;Mauricio Etchebehere ,&nbsp;Elba Etchebehere","doi":"10.1016/j.htct.2025.103771","DOIUrl":"10.1016/j.htct.2025.103771","url":null,"abstract":"<div><h3>Introduction/Justification</h3><div>Soft tissue musculoskeletal sarcoma (STS) is a rare and varied class of mesenchymal-derived malignancies. Due to its histopathological heterogeneity and presence in different body locations, its diagnosis and treatment continue to present a significant medical challenge. In nuclear medicine, 18F-FDG PET/CT (FDG PET/CT) has been used to grade sarcomas, predict their prognosis, and assess therapy response. Although prostate-specific membrane antigen (PSMA) has been mainly used to detect prostate cancer metastases with PSMA PET/CT imaging and treat with 225Ac/177Lu-PSMA, this antigen has been shown to accumulate in non-prostatic tissues, including several types of sarcomas.</div></div><div><h3>Objectives</h3><div>Evaluate the potential of PSMA PET/CT in diagnosing different types of STSs compared to FDG PET/CT, with the aim of expanding the clinical management of these patients and the potential of a Theranostics strategy with radiolabeled PSMA.</div></div><div><h3>Materials and Methods</h3><div>Forty-four participants (20 females) with STS were prospectively enrolled and submitted to FDG PET/CT and PSMA PET/CT for primary staging, with a 48-hour interval between studies. SUVmax values were obtained in both studies of the primary STS lesion, locoregional lymph node metastases (LRLNs), distant lymph node metastases (DLNs), and bone metastases. SUVmax values among FDG PET/CT and PSMA PET/CT studies were normalized using the mediastinum SUVmax as a standard reference. The number of metastases detected by FDG PET/CT and PSMA PET/CT were also compared, as well as the absolute SUVmax values.</div></div><div><h3>Results</h3><div>The absolute SUVmax values were higher on PSMA PET/CT compared to FDG PET/CT, respectively for the primary STS lesions (18.5 vs 12.8), for LRLNs (8.0 vs 4.5) and bone metastases (8.7 vs 3.2), while these values were similar for DLNs (3.0 vs 4.0). When the SUVmax values were normalized using the mediastinum as a reference the ratio comparing PSMA PET/CT to FDG PET/CT showed, respectively: 10.3 vs 5.3 for the primary STS; 4.7 vs 2.0 for LRLNs; 4.8 vs 2.9 for bone metastases; and 1.7 vs 1.7 for DLNs. PSMA PET/CT detected more LRLNs compared to FDG PET/CT (10 patients vs 7 patients, respectively) and more bone metastases (5 patients vs 3 patients). The detectability of DLNs was equal in both studies (7 patients).</div></div><div><h3>Conclusion</h3><div>Our preliminary findings indicate that PSMA PET/CT is a potential diagnostic tool for staging sarcomas patients. Due to the high uptake in the primary STS lesions and metastases, there is a potential for a theranostics approach. This study received financial support from the São Paulo State Foundation for Teaching and Research Support (Cancer Theranostics Innovation Center, (CancerThera), CEPID FAPESP #2021/10265-8).</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 ","pages":"Article 103771"},"PeriodicalIF":1.8,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143829762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PET/CT WITH ¹⁸F-FDG AND ¹⁸F-PSMA IN LUNG CANCER: DIFFERENCES BETWEEN ADENOCARCINOMA AND SQUAMOUS CELL CARCINOMA","authors":"Najua Abou Arabi Silveira,&nbsp;Maurício Wesley Perroud Júnior,&nbsp;Maria Emilia Seren Takahashi,&nbsp;Kaique Moraes do Amaral,&nbsp;Simone Kuba,&nbsp;Bárbara Juarez Amorim,&nbsp;Mariana da Cunha Lopes de Lima,&nbsp;Carmino Antonio de Souza,&nbsp;Carmen Silvia Passos Lima,&nbsp;Celso Dario Ramos","doi":"10.1016/j.htct.2025.103799","DOIUrl":"10.1016/j.htct.2025.103799","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction/Justification&lt;/h3&gt;&lt;div&gt;Lung cancer remains a leading cause of mortality worldwide. PET/CT with ¹⁸F-FDG is widely used for detecting, staging, and monitoring lung cancer by assessing increased glycolytic metabolism in tumor cells. Prostate-specific membrane antigen (PSMA), although primarily a marker for prostate cancer, is also associated with tumor neoangiogenesis and has shown uptake in various malignancies, including lung cancer, suggesting potential theranostic applications.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objectives&lt;/h3&gt;&lt;div&gt;This study aims to compare the uptake of ¹⁸F-FDG and ¹⁸F-PSMA in primary and metastatic lung cancer lesions, analyzing differences between adenocarcinoma and squamous cell carcinoma (SCC) subtypes.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Materials and Methods&lt;/h3&gt;&lt;div&gt;Fourteen patients (9 men and 5 women), aged 55–82 years and diagnosed with lung cancer (10 adenocarcinoma, 4 SCC), underwent PET/CT scans on two separate days: 60 minutes after intravenous administration of 0.1 mCi/kg of ¹⁸F-FDG and 90 minutes after intravenous administration of 0.1 mCi/kg of ¹⁸F-PSMA. Images were assessed by two nuclear medicine physicians and one radiologist. The maximum standardized uptake value (SUVmax) was measured for both tracers in primary tumors, regional lymph nodes, and distant metastatic lesions. The lesions were defined in both tracers by an SUVmax uptake above the background and visual analysis.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;A total of 288 lesions were analyzed (247 adenocarcinoma, 41 SCC). In adenocarcinoma, ¹⁸F-PSMA identified 215 lesions, compared to 237 detected by ¹⁸F-FDG. Nine lesions were exclusive to ¹⁸F-PSMA, while 32 were detected only by ¹⁸F-FDG. Forty-five lesions showed higher ¹⁸F-PSMA uptake, while 174 exhibited predominant ¹⁸F-FDG uptake. The median SUVmax for ¹⁸F-FDG was 6.5 (range: 1.8–24.5), compared to 4.0 (range: 0.7–24.8) for ¹⁸F-PSMA. In SCC, ¹⁸F-PSMA identified 36 lesions, while ¹⁸F-FDG detected 41. No lesions showed predominant ¹⁸F-PSMA uptake, and SUVmax values were higher for ¹⁸F-FDG (median: 8.8; range: 1.3–36.6) compared to ¹⁸F-PSMA (median: 2.5; range: 0.9–10.4).We found that SUV values for ¹⁸F-PSMA are statistically different between SCC and adenocarcinoma subtypes in the lesions that showed uptake of both radiotracers (Mann-Whitney U test, p-value &lt; 0.0001). Also, a positive correlation was observed for ¹⁸F-FDG and ¹⁸F-PSMA SUVs in both histological subtypes, being strong for SCC (r = 0.0,8140, p-value &lt; 0.0001) and moderate for adenocarcinoma (r = 0.4278, p-value &lt; 0.0001).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;These findings highlight distinct uptake patterns between adenocarcinoma and SCC using ¹⁸F-FDG and ¹⁸F-PSMA PET/CT. SCC demonstrated markedly higher ¹⁸F-FDG uptake with minimal ¹⁸F-PSMA uptake, indicating limited utility of ¹⁸F-PSMA in this subtype. In contrast, adenocarcinoma showed higher ¹⁸F-FDG uptake in most lesions, but a subset exhibited significant ¹⁸F-PSMA uptake, suggest","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 ","pages":"Article 103799"},"PeriodicalIF":1.8,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143829763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PRODUCING IODINE-131 FROM TELLURIUM-130 NEUTRON ACTIVATION: STUDY OF FEASIBILITY IN THE ARGONAUTA RESEARCH REACTOR AT IEN","authors":"LUCIANA CARVALHEIRA ,&nbsp;Ramon Matias Nunes MENDONÇA ,&nbsp;Francisco José de Oliveira FERREIRA ,&nbsp;Rogerio Chaffin NUNES","doi":"10.1016/j.htct.2025.103812","DOIUrl":"10.1016/j.htct.2025.103812","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction/Justification&lt;/h3&gt;&lt;div&gt;Modern oncology faces challenges when treating elderly patients, who often have limited responses to conventional chemotherapy. To address this, theranostics combines diagnostic and therapeutic properties of radioisotopes in the same molecule, enabling personalized medicine. Iodine-131 (I-131) is a pioneering theranostic radionuclide widely used in Nuclear Medicine, for thyroid cancer due to its high affinity for thyroid tissue and beta and gamma radiation emission. In Brazil, the production and supply of I-131 are managed by the Nuclear and Energy Research Institute (IPEN) in São Paulo. However, delivering short-lived radioisotopes to remote regions presents challenges that may cause delays, affecting clinical and research applications. This highlights the need for alternative production methods to ensure timely availability of crucial radionuclides. This study explores the feasibility of producing I-131 through neutron activation of tellurium-130 at the Argonauta Research Reactor at the Nuclear Engineering Institute (IEN) in Rio de Janeiro. The Argonauta reactor, in operation since 1965, has been used for R&amp;D in nuclear technology and the training of human resources for Brazil's Nuclear Program. Its team has optimized I-131 synthesis from tellurium-130 via neutron activation. The reactor's Nuclear Instrumentation and Radiochemistry laboratories are equipped for radiochemical processing, purification, and gamma spectrometry. Developing a validated I-131 production method at IEN would benefit local research and reduce dependence on external suppliers.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Report&lt;/h3&gt;&lt;div&gt;In the methodology, high-purity tellurium dioxide (TeO2) was irradiated for one hour at a neutron flux of 10^9 n/cm²·s. After irradiation, I-131 was isolated using a radiochemical separation process. The irradiated oxide was dissolved in sodium hydroxide solution (4 mol/L), followed by hydrochloric acid (1 mol/L) addition to adjust the pH to 5-6. The separation method ensured I-131 retention in the aqueous phase. Gamma spectrometry confirmed radionuclide half-life, radionuclidic purity, and activity levels. The results demonstrated successful I-131 production with radionuclide purity over 95% within four hours post-irradiation. The highest activity was observed approximately 10 hours after neutron activation. Decay curve analysis confirmed the expected half-life of 8.025 days, consistent with literature values. The study also highlighted the efficiency of the radiochemical separation method in minimizing contamination from tellurium-131.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;These findings indicate that the proposed method is a viable alternative for local I-131 production, particularly for research purposes. While the activity levels achieved are suitable for experimental applications, further optimizations, such as increasing neutron flux, extending irradiation time, or improving chemical processing efficiency, ","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 ","pages":"Article 103812"},"PeriodicalIF":1.8,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143828175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MESENCHYMAL PHOSFATURIC TUMOR: A CASE REPORT OF SUCCESS","authors":"GARDENIA BARBOSA ,&nbsp;Natália TOBAR ,&nbsp;Monique OHE ,&nbsp;Karina ARAUJO ,&nbsp;Maurício ETCHEBEHERE ,&nbsp;Elba ETCHEBEHERE","doi":"10.1016/j.htct.2025.103816","DOIUrl":"10.1016/j.htct.2025.103816","url":null,"abstract":"<div><h3>Introduction/Justification</h3><div>Hypophosphatemia mesenchymal tumors (HMT) are rare, of uncertain origin, and may cause osteomalacia derived from paraneoplastic syndrome. The clinical manifestations are caused mainly by phosphatase secretion promoted by the tumor cells, leading to excessive kidney excretion of phosphate, fractures, bone pain, hypophosphatemia, and low calcitriol levels. HMTs are challenging to locate through anatomic imaging because they are relatively small and occult.</div></div><div><h3>Report</h3><div>We describe a case that illustrates the potential of nuclear medicine to identify HMT. A 52-year-old female patient complained of diffuse pain, especially in the hips, rib cage, and feet, for over one year. Magnetic resonance imaging (MRI) of the hip demonstrated bilateral avascular necrosis of the femoral heads. To evaluate a possible osteometabolic alteration, such as hyperparathyroidism, she underwent bone scintigraphy, which did not reveal signs of hyperparathyroidism but identified (in addition to the avascular necrosis) signs of hypertrophic osteoarthropathy, suggesting paraneoplastic syndrome. Laboratory tests showed normal PTH, hypophosphatemia, and phosphaturia. The patient initiated oral phosphorus replacement, which only partially reduced bone pain. She was submitted to an FDG-18F PET/CT to search for an occult tumor, which was negative. Considering the patient´s phosphaturia and reports of hypophosphatemia and osteomalacia caused by occult non-mesenchymal tumors of the soft tissues, the hypothesis of phosphate-producing HMT was considered. These tumors arise mainly in the lower limbs, generate pain and a predisposition to small fractures in subchondral bones (more common in the femoral heads), and express somatostatin receptors. Thus, a DOTATATE-68Ga PET/CT was performed to locate this somatostatin-expressing occult tumor. The images showed a 0.5 cm intramuscular nodule with hyperexpression of somatostatin receptors deep within the left thigh muscle. To prepare for surgery, an MRI of the left thigh was performed to locate the nodule with DOTA-68Ga uptake. MRI showed the nodule was quite deep within the muscle and close to the left femoral vascular-nerve bundle. Due to the lesion's small size, deep location, and proximity to the neurovascular bundle, radioguided surgery with DOTA-68Ga was performed to remove the nodule. Histopathology concluded the nodule was consistent with a hypophosphatemia mesenchymal tumor. After the removal of the tumor, the phosphate level normalized, the pain disappeared, and the patient reported improved physical and mental health.</div></div><div><h3>Conclusion</h3><div>In conclusion, a bone scan was essential to identify the possibility of an occult tumor due to the imaging characteristics of paraneoplastic syndrome, and the DOTATATE-68Ga PET/CT was vital to locate the tumor.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 ","pages":"Article 103816"},"PeriodicalIF":1.8,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143828179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"APPLICABILITY OF PSMA PET/CT IN THE EVALUATION OF ADENOID CYSTIC CARCINOMA","authors":"Lucas Pinho,&nbsp;Ellen Lima,&nbsp;Natália Tobar,&nbsp;Simone Kuba,&nbsp;Hádila Sousa,&nbsp;Lígia Macedo,&nbsp;Allan Santos,&nbsp;Carmen Lima,&nbsp;Elba Etchebehere","doi":"10.1016/j.htct.2025.103809","DOIUrl":"10.1016/j.htct.2025.103809","url":null,"abstract":"<div><h3>Introduction/Justification: Introduction</h3><div>Adenoid Cystic Carcinoma (ACC) is a rare and aggressive tumor characterized by slow and indolent growth, high recurrence, high metastasis rates, and challenging early detection, and 18F-FDG PET/CT imaging has become essential for diagnosis, staging, and monitoring of it. In the last decade, the promising theranostic approach of 18F-PSMA PET/CT for prostate carcinoma has led to the evaluation of PSMA target with 18-Fluor (diagnostic) and 177-Lutetium (therapeutic) in ACC, whose cells overexpress this surface antigen.</div></div><div><h3>Justification</h3><div>As it is a recent discovery, further studies are needed to evaluate the use of 18F-PSMA PET/CT to predict the prognosis and assess therapy response in ACC cases.</div></div><div><h3>Research Question</h3><div>Could 18F-PSMA PET/CT, compared to 18F-FDG PET/CT, be used as a diagnostic technique for ACC and, as a consequence, labeled PSMA be potentially a therapeutic resource for this cancer?</div></div><div><h3>Objective</h3><div>Evaluate the applicability of 18F-PSMA PET/CT compared to 18F-FDG PET/CT in the management of ACC.</div></div><div><h3>Materials and Methods</h3><div>Five patients (A, B, C, D, and E) diagnosed with ACC underwent 18F-FDG PET/CT and 18F-PSMA PET/CT (24-hour intervals, except by two cases), and the lesions uptakes were evaluated with both radiotracers.</div></div><div><h3>Preliminary Results</h3><div>Patient A showed hypermetabolism only for 18F-FDG PET/CT at cervical lymph nodes; B exhibited an uptake substantially higher on 18F-FDG PET/CT at the primary lesion site, cervical lymph nodes, and lung (46 days between the exams and after treatment with doxorubicin); C and D showed similar uptake on both tracers: C at L5 vertebra and lung, and D at lung; E exhibited uptake of both tracers, in cervical lymph nodes with 18F-FDG, suggesting inflammation, and in the lung with 18F-PSMA.</div></div><div><h3>Discussion</h3><div>Preliminary data suggest similar uptake patterns for both tracers in ACC, with variations warranting further investigation.</div></div><div><h3>Conclusion</h3><div>The study highlights the potential use of 18F-PSMA PET/CT in the diagnostic management of ACC, expanding its possible therapeutic application.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 ","pages":"Article 103809"},"PeriodicalIF":1.8,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143828174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"“ARMADILHA” NA ESTRATÉGIA DA RADIOEMBOLIZAÇÃO HEPÁTICA COM ÍTRIO90 NAS METÁSTASES DE CARCINOMA DE CÓLON. RELATO DE CASO","authors":"MARCIA GARRIDO MODESTO TAVARES,&nbsp;Ingrid Guiname BLOISE,&nbsp;Mariana Ramos FERNANDES CAMACHO,&nbsp;Jose Geraldo ALMEIDA FILHO,&nbsp;Irene shimura ENDO,&nbsp;Fabiana Lucas BUENO","doi":"10.1016/j.htct.2025.103814","DOIUrl":"10.1016/j.htct.2025.103814","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introdução/Justificativa&lt;/h3&gt;&lt;div&gt;O câncer colorretal é a segunda causa de morte relacionada ao câncer no mundo. Aproximadamente metade dos pacientes apresenta metástase hepática ao diagnóstico ou no curso do tratamento. A ressecção cirúrgica com intenção curativa contempla apenas 20% dos casos. A maioria é considerada irressecável, sendo submetida a tratamento sistêmico. A radioembolização interna seletiva (SIRT) com microesferas de ítrio90 tem desempenhado importante papel na estratégia terapêutica das metástases hepáticas por câncer de cólon com aumento da sobrevida livre de progressão.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Relato&lt;/h3&gt;&lt;div&gt;Este é o caso de um homem de 54 anos, submetido a cirurgia por obstrução intestinal em agosto de 2022, com diagnóstico de adenocarcinoma de cólon direito já com metástases hepáticas. Iniciou quimioterapia sistêmica (QT) e após progressão hepática, iniciou segunda linha de QT no início de 2023. O estudo de PET/CT evidenciava quatro lesões no lobo direito e uma lesão no segmento IVa, sem evidência de doença extra-hepática e pequena área de dilatação biliar associado a diminuto foco de captação no segmento II. A RNM apresentava os mesmos nódulos e referia pequena dilatação biliar no segmento II, sem caracterização de fator obstrutivo. Paciente foi submetido a radioembolização hepática com itrio90, com excelente concentração nas 5 lesões hepáticas secundárias. Foi administrado itrio90 seletivamente no segmento IVa (maior lesão, 0,4 Gbq correspondendo pelo Partition a 200Gy no tumor), segmento VI (0,4Gbq com 200Gy nas duas lesões), e de forma não seletiva no tronco que irrigava os segmentos V/VIII e VI/VII (1,0 Gbq). Optou-se por não abordar a mínima área de dilatação biliar no segmento II devido à ausência de lesão na RNM. Paciente evoluiu bem, PET/CT realizado 3 meses após o tratamento mostrou resposta excelente na lesão do segmento IVa, resposta completa nas outras 4 lesões, porém crescimento significativo das dimensões e captação da lesão associada a dilatação biliar no segmento II não tratado. Encaminhado para radioablação da lesão remanescente. A RNM 3 meses após, apresentava ausência de doença hepática ativa, significativa redução das dimensões do lobo hepático direito e hipertrofia do lobo caudado e lobo esquerdo. Teve férias da QT por 6 meses quando foi evidenciado nova progressão de doença hepática associado a obstrução biliar e doença secundária pulmonar, sendo submetido a procedimento de drenagem biliar e reiniciado tratamento sistêmico.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusão&lt;/h3&gt;&lt;div&gt;O sucesso do tratamento locorregional das metástases hepáticas no câncer de cólon está relacionado a um bom planejamento e entrega do itrio90 nas lesões. O caso descrito nos ensina que houve boa resposta ao itrio90 nas áreas tratadas, que focos pequenos de doença merecem atenção pois podem ser os vilões no futuro e que o PET/CT foi mais sensível na detecção precoce de lesão hepática pequena ávida a glicose. Nosso paciente superou a expect","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 ","pages":"Article 103814"},"PeriodicalIF":1.8,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143828177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CASE REPORT OF METASTATIC MELANOMA LESION AFFECTING AN EXTENSIVE AREA OF THE LEFT LOWER LIMB ON 18F-PSMA PET/CT AND 18F-FDG PET/CT IMAGES – INTENDING TO COMPARE THE DISTRIBUTION OF BOTH RADIOTRACERS IN THIS CANCER","authors":"LARISSA MANSANO DE SOUZA,&nbsp;Thiago Soares Rocha ALVES,&nbsp;Diego Machado MENDANHA,&nbsp;Ellen LIMA,&nbsp;Natália TOBAR,&nbsp;Juliana P SOUZA,&nbsp;Ligia Traldi MACEDO,&nbsp;Allan Oliveira SANTOS,&nbsp;Mariana Cunha Lopes de LIMA,&nbsp;Elba Cristina Sa de Camargo ETCHEBEHERE,&nbsp;Carmen Silvia Passos LIMA","doi":"10.1016/j.htct.2025.103815","DOIUrl":"10.1016/j.htct.2025.103815","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction/Justification&lt;/h3&gt;&lt;div&gt;Positron emission tomography (PET/CT) using 18F-FDG has been widely used for staging and monitoring melanoma patients. Recent studies highlight the potential of 18F-PSMA PET/CT as an additional diagnostic modality, given the expression of prostate-specific membrane antigen (PSMA) in melanoma cells. Recent evidence indicates that anti-PSMA antibodies react with malignant melanoma neo vasculature, coupled with incidental findings reporting PSMA avidity in melanoma, the potential role of 18F-PSMA PET/CT as a novel diagnostic imaging technique in non-prostatic cancers looks promising.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Report&lt;/h3&gt;&lt;div&gt;We describe below a case that illustrates the potential of 18F-PSMA PET/CT in evaluate melanoma lesions: 72-year-old female patient, Caucasian, single, with medical history of chronic obstructive pulmonary disease, diabetes mellitus, hypertension, smoking for 10 years (50 pack-years), and a cerebral aneurysm clipping in 2013 (which resulting in inability to walk). In 2022, she developed a sudden and progressive lesion on her left hallux, which spread to left lower limb over six months. She underwent two biopsies, confirming the diagnosis of melanoma. In 2024, the subject presented on physical examination a lesion affecting all the posterior portion of the lower limb, associated to an ulcerated vegetative lesion of approximately 10 cm on the medial portion of the left hallux. The immunohistochemistry findings described an invasive and ulcerated melanoma (Breslow 5 mm). On 16-October-2024 she underwent a 18F-FDG PET/CT founding an extensive densification of the subcutaneous tissue throughout the entire left lower limb, associated with multiple nodules, measuring up to 6.8 × 3.2 cm (SUVmax = 36.9). Furthermore, it was found left inguinal and femoral lymphadenopathy, and multiple pulmonary and hepatic nodules (SUVmax = 30.3). On the following day (17-October-2024), it was performed a 18F-PSMA PET/CT which found uptake of the radiotracer on the primary lesion in the left lower limb (SUBmax = 22.7), in the regional lymph nodes (inguinal and femoral) and pulmonary nodules (SUVmax = 32.1). Comparatively, the 18F-PSMA radiotracer showed smoothly less intense uptake in the left lower limb lesion and pulmonary nodules compared to 18F-FDG. On the other hand, hepatic nodules did not present 18F-PSMA uptake, while 18F-FDG uptake was moderately intense (SUVmax = 9.7). Due to the patient's multiple comorbidities, advanced age, poor general condition (Karnofsky Performance Status of 40%), and high surgical risk, invasive treatment was contraindicated. Palliative care was chosen instead.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;Therefore, apart from the use of 18F-PSMA PET/CT in staging of prostate cancer patients, this method shows a great potential in the evaluating of metastatic melanoma, with a capacity of uptake in lesions comparable to 18F-FDG PET/CT (as demonstrated in this case), needing further and l","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 ","pages":"Article 103815"},"PeriodicalIF":1.8,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143828178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EGFR-TARGETING PEPTIDE INHIBITS HELA CELL PROLIFERATION: A NOVEL STRATEGY FOR CERVICAL CANCER THERAPY?","authors":"Reem Hussin,&nbsp;Danielle Vieira Sobral,&nbsp;Fernanda Ferreira Mendonça,&nbsp;Leonardo Lima Fuscaldi,&nbsp;Luciana Malavota","doi":"10.1016/j.htct.2025.103785","DOIUrl":"10.1016/j.htct.2025.103785","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction/Justification&lt;/h3&gt;&lt;div&gt;Cervical cancer remains one of the leading causes of cancer-related mortality in women worldwide, with EGFR overexpression contributing to uncontrolled proliferation, resistance to apoptosis, and tumor progression. Despite advances in radiotherapy and chemotherapy, many patients develop resistance, highlighting the urgent need for targeted therapies that can disrupt these oncogenic pathways. Peptide-based drugs represent a promising avenue for precision oncology, offering high specificity, low toxicity, and potential to inhibit key molecular drivers of cancer. This study investigates the YHWYGYTPQNVT peptide, designed to interact with EGFR, and evaluates its effect on proliferation and migration of HeLa cells, a widely used model of cervical cancer.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objectives&lt;/h3&gt;&lt;div&gt;This research aims to determine whether the YHWYGYTPQNVT peptide can effectively suppress EGFR-mediated growth signaling in HeLa cells, by analyzing cell proliferation, metabolic activity, and migration, aiming at establishing its potential as a therapeutic alternative to traditional cancer treatments.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Materials and Methods&lt;/h3&gt;&lt;div&gt;The YHWYGYTPQNVT peptide was synthesized using solid-phase peptide synthesis, purified via HPLC, and confirmed by mass spectrometry. HeLa cells were cultured in DMEM + 10% fetal bovine serum and incubated at 37°C with 5% CO₂. To establish a baseline proliferation rate, HeLa cells were plated at 5 × 104 cells in 6-well plates, and the growth curve was performed in sextuplicate over a 5-days period, with cell counts conducted on days 1, 3 and 5. For the experimental group, cells were treated with YHWYGYTPQNVT (80 µmol/mL). Statistical analysis was conducted using GraphPad Prism, with significance set at p ≤ 0.05.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;The YHWYGYTPQNVT peptide was synthesized efficiently with yield of approximately 45%. Chromatographic analyzes obtained by HPLC and mass spectrometry confirmed that the entire synthesis, cleavage, and purification process of peptides were performed efficiently. Control group displayed an aggressive proliferation rate with an exponential growth, reaching ∼96.8 × 10⁴ cells, consistent with the known oncogenic potential of HeLa cells. In contrast, the peptide-treated group showed a significant reduction in proliferation, with final cell counts averaging 61.5 × 10⁴ cells - corresponding to a 25.5% decrease compared to untreated cells.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;Our findings highlight YHWYGYTPQNVT as a promising EGFR-targeting agent capable of reducing cervical cancer cell proliferation. By directly interfering with EGFR-driven oncogenic pathways, this approach could lay the groundwork for a new class of peptide-based therapeutics in oncology. Further in vivo validation and molecular pathway analysis are necessary to determine its potential clinical application in patients with EGFR-overexpressing cervical tumors.&lt;/div","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 ","pages":"Article 103785"},"PeriodicalIF":1.8,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143828825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}